Rocket Pharmaceuticals (RCKT) Investor Presentation - Slideshow

Rocket Program Updates Following ASGCT 2022 Danon Disease, Pyruvate Kinase Deficiency, Fanconi Anemia, and Leukocyte Adhesion Deficiency-I 1 Gaurav Shah, MD Chief Executive Officer May 20, 2022 S E E K I N G G E N E T H E R A P Y C U R E S NASDAQ: RCKT 2 Cautionary Statement Regarding Forward-Looking Statements Various statements in this release concerning Rocket's future expectations, plans and prospects, including without limitation, Rocket's expectations regarding its guidance for 2022 in light of COVID- ...